Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)

First Posted Date: 2008-01-11

Last Posted Date: 2023-09-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 70

Registration Number: NCT00591851

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Cancer Control Following Polypectomy

Completed

Conditions: Colon Cancer

First Posted Date: 2008-01-11

Last Posted Date: 2023-09-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 110

Registration Number: NCT00591279

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas

Phase 2

Completed

Conditions: Malignant Gliomas
CNS
Brain Cancer
Cancer

Interventions: Drug: Perifosine

First Posted Date: 2008-01-11

Last Posted Date: 2020-10-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 32

Registration Number: NCT00590954

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)

Phase 1

Completed

Conditions: Adrenal Tumors
Adrenal Malignancies
Electrolytes Abnormalities
Abnormal Hormonal Secretions

Interventions: Procedure: Imaging, Adrenal acans
Radiation: (NP-59)

First Posted Date: 2008-01-11

Last Posted Date: 2015-12-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 93

Registration Number: NCT00591643

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer

Phase 2

Completed

Conditions: Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer

First Posted Date: 2008-01-11

Last Posted Date: 2023-10-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 81

Registration Number: NCT00590902

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Temozolomide (TMZ)

First Posted Date: 2008-01-11

Last Posted Date: 2023-07-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 51

Registration Number: NCT00591370

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: Sho-saiko-to

First Posted Date: 2008-01-10

Last Posted Date: 2016-01-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 42

Registration Number: NCT00590564

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Pemetrexed plus Gemcitabine

First Posted Date: 2008-01-10

Last Posted Date: 2014-04-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 26

Registration Number: NCT00589667

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.

Phase 2

Completed

Conditions: Esophageal Carcinoma

Interventions: Drug: Cisplatin
Drug: Irinotecan
Radiation: External Beam Radiation Therapy

First Posted Date: 2008-01-10

Last Posted Date: 2016-01-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 61

Registration Number: NCT00590031

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

Phase 2

Completed

Conditions: CNS Cancer
Intracranial Hemangiopericytoma
Meningioma
Hemangioblastoma
Neurofibromatosis

Interventions: Drug: Sunitinib

First Posted Date: 2008-01-10

Last Posted Date: 2016-01-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 50

Registration Number: NCT00589784

Locations: 🇺🇸
University of Virginia Health Science Center, Charlottesville, Virginia, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy